• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Tiziana Life Sciences plc

    1/4/22 4:31:31 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLSA alert in real time by email
    SC 13D 1 ea153438-13dcerrone_tiziana.htm SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Tiziana Life Sciences Ltd.

    (Name of Issuer)

     

    Common Shares, Par Value $0.001 Per Share

    (Title of Class of Securities)

     

    (CUSIP Number)

     

    Gabriele M. Cerrone

    Planwise Group Limited

    3/f J & C Building, Roadtown,

    Tortola British Virgin Islands

    With a copy to:

     

    Jeffrey Fessler

    Sheppard Mullin Richter & Hampton LLP

    30 Rockefeller Plaza

    New York, NY 10112

    (212) 653-8700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    October 20, 2021

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 

    1.

    Names of Reporting Person.

     

    Planwise Group Limited

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions):

     

    (a)  ☐

    (b)  ☐ 

    3.

    SEC Use Only:

     

     

    4.

    Source of Funds (See Instructions):

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e): ☐

     

     

    6.

    Citizenship or Place of Organization:

     

    British Virgin Islands

    Number of Shares Beneficially Owned by Each Reporting Person with 7.

    Sole Voting Power:

     

     

    8.

    Shared Voting Power:

     

    31,648,823

    9.

    Sole Dispositive Power:

     

     

    10.

    Shared Dispositive Power:

     

    31,648,823

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

    31,648,823

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions): ☐

     

     

    13.

    Percent of Class Represented by Amount in Row (11):

     

    35.53%

    14.

    Type of Reporting Person (See Instructions):

     

    PN

     

    -2-

     

     

    CUSIP No.

    1.

    Names of Reporting Person.

     

    Panetta Partners Limited

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions):

     

    (c)  ☐

    (d)  ☐

    3.

    SEC Use Only:  

     

     

    4.

    Source of Funds (See Instructions):

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e): ☐

     

     

    6.

    Citizenship or Place of Organization:

     

    British Virgin Islands 

    Number of Shares Beneficially Owned by Each Reporting Person with 7.

    Sole Voting Power:

     

     

    8.

    Shared Voting Power:

     

    6,873,762

    9.

    Sole Dispositive Power:

     

     

    10.

    Shared Dispositive Power:

     

    6,873,762 

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

    6,873,762

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions): ☐

     

     

    13.

    Percent of Class Represented by Amount in Row (11):

     

    7.06%

    14.

    Type of Reporting Person (See Instructions):

     

    PN

     

    -3-

     

     

    CUSIP No. 

    1.

    Names of Reporting Person.

     

    Gabriele M. Cerrone

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions):

     

    (e)  ☐

    (f)   ☐

    3.

    SEC Use Only:

     

     

    4.

    Source of Funds (See Instructions):

     

    OO

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e): ☐

     

     

    6.

    Citizenship or Place of Organization:

     

    Monaco

    Number of Shares Beneficially Owned by Each Reporting Person with 7.

    Sole Voting Power:

     

     

    8.

    Shared Voting Power:

     

    38,522,585

    9.

    Sole Dispositive Power:

     

     

    10.

    Shared Dispositive Power:

     

    38,522,585

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions): ☐

     

     

    13.

    Percent of Class Represented by Amount in Row (11):

     

    39.59%

    14.

    Type of Reporting Person (See Instructions):

     

    IN

     

    -4-

     

     

    Item 1. Security and Issuer.

     

    This filing on Schedule 13D relates to the common shares, par value $0.001 per share (the “Common Shares”) of Tiziana Life Sciences Ltd., a Bermuda corporation (“Tiziana”), whose principal executive offices are located at 9th Floor, 07 Cheapside, London EC2V 6DN, United Kingdom.

     

    Item 2. Identity and Background.

     

    (a)This report is being filed jointly by the following person (collectively, the “Reporting Person”)*:

     

    ●Planwise Group Limited, a British Virgin Islands investment corporation (“Planwise”)
      3/f J & C Building, Roadtown, Tortola British Virgin Islands
       
    ●Panetta Partners Limited, a British Virgin Islands investment corporation (“Panetta”)
      3/f J & C Building, Roadtown, Tortola British Virgin Islands

     

    ●Mr. Gabriele M. Cerrone, a citizen of Monaco (“Mr. Cerrone”)
      3/f J & C Building, Roadtown, Tortola British Virgin Islands]

     

    *The Reporting Persons have entered into a joint filing agreement, dated as of January 4, 2022, a copy of which is attached hereto as Exhibit 1.

     

    Mr.Cerrone is director of Planwise and Panetta.

     

    (b)See Item 2(a) above.

     

    (c)Planwise Group Limited

     

    Planwise is a British Virgin Islands investment corporation

     

    Panetta Partners Limited

     

    Panetta is a British Virgin Islands investment corporation

     

    Mr.Gabriele M. Cerrone

     

    Theprincipal occupation of Mr. Cerrone is Director.

     

    (d)During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)See Item 2(a) above.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    The Reporting Persons beneficially own an aggregate of 38,489,256 Common Shares (the “Subject Shares”).

     

    The Subject Shares were acquired by or on behalf of the Reporting Persons by Planwise Ltd and Panetta Partners Ltd.

     

    -5-

     

     

    Item 4. Purpose of Transaction.

     

    The Reporting Persons do not have any present plans or proposals of the types set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may, from time to time, acquire additional Common Shares or dispose of all or a portion of the Tiziana Common Shares that he beneficially owns, either in the open market or in privately negotiated transactions.

     

    Item 5. Interest in Securities of the Issuer.

     

    (a)and (b)

     

    The aggregate percentage of the outstanding Common Shares reported as beneficially owned by each Reporting Person is based upon the 97,306,144 Common Shares disclosed by the Issuer (adjusted for consolidation) as outstanding as of September 27, 2021, as reported by Tiziana in its __6-K___ filed with the Securities and Exchange Commission on ___September 27, 2021___. 

     

    Planwise beneficially owns and has the shared power to vote or direct the vote of, and the shared power to dispose or direct the disposition of, the Subject Shares, representing 32.53% of the outstanding Common Shares. Panetta beneficially owns and has the shared power to vote or direct the vote of, and the shared power to dispose or direct the disposition of, the Subject Shares, representing 7.06% of the outstanding Common Shares. By virtue of Mr. Cerrone’s position as the director of each of Planwise and Panetta, Mr. Cerrone beneficially owns, and has the shared power to vote or direct the vote of, and the shared power to dispose or direct the disposition of, the Subject Shares, representing 39.59% of the outstanding Common Shares.

     

    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission by any Reporting Person that they constitute a “group” for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and the Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (b)No other person is known to the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Subject Shares, except that each Reporting Person has the right to receive dividends from, and proceeds from the sale of, the Common Shares held of record by each.

     

    (c)Not applicable.

     

    (d)Not applicable.

     

    (e)Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

     

    None.

     

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit 1: Joint Filing Agreement, dated January 4, 2022.

     

    -6-

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: January 4, 2022

     

    PLANWISE GROUP LIMITED
           
    By: /s/ Gabriele Cerrone
      Name:  Gabriele Cerrone
      Title: Director

     

      PANETTA PARTNERS LIMITED
           
    By: /s/ Gabriele Cerrone
      Name:  Gabriele Cerrone
      Title: Director

     

      GABRIELE M. CERRONE
       
      /s/ Gabriele M. Cerrone

     

    -7-

     

     

    EXHIBIT 1

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to such statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entity or person, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated:January 4, 2022 PLANWISE GROUP LIMITED
           
      By: /s/ Gabriele Cerrone
        Name:  Gabriele Cerrone
        Title: Director

     

    PANETTA PARTNERS LIMITED
           
      By: /s/ Gabriele Cerrone
        Name:  Gabriele Cerrone
        Title: Director
           
      GABRIELE M. CERRONE
           
      /s/ Gabriele M. Cerrone

     

     

     

     

    Get the next $TLSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TLSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

      Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores.TSPO-PET imaging showed significant reductions in microglial activation at six months (p<0.05). NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced promising results from an open-label clinical study evaluat

      5/6/25 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

      NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The University of Massachusetts (UMass) has now joined Brigham and Women's Hospital (BWH), Yale Multiple Sclerosis Center, and Johns Hopkins University (JHU) Autoimmunity Center of Excellence

      4/23/25 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

      NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, the third clinical site in its Phase 2 trial evaluating intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Other active clinical sites in the study include Brigham and Women's Hospital (BWH) and MS Center at Yale Medical Center. The randomiz

      4/2/25 8:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    SEC Filings

    See more

    $TLSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TLSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 6-K filed by Tiziana Life Sciences Ltd.

      6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/9/25 7:00:19 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 20-F/A filed by Tiziana Life Sciences Ltd.

      20-F/A - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/8/25 5:00:51 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Tiziana Life Sciences Ltd.

      20-F - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/6/25 5:02:01 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Tiziana Life Sciences Ltd.

      SC 13G - Tiziana Life Sciences Ltd (0001723069) (Subject)

      5/4/22 4:34:27 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Tiziana Life Sciences plc

      SC 13D - Tiziana Life Sciences Ltd (0001723069) (Subject)

      1/4/22 4:31:31 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Tiziana Life Sciences plc (0001723069) (Subject)

      2/16/21 7:32:16 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zacks Investment Research initiated coverage on Tiziana Life Sciences with a new price target

      Zacks Investment Research initiated coverage of Tiziana Life Sciences with a rating of Not Rated and set a new price target of $7.50

      4/12/21 11:57:17 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Financials

    Live finance-specific insights

    See more
    • Tiziana Life Sciences Announces Date of Annual General Meeting 2022

      NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company will be held on December 29, 2022. The record date for voting at the Annual General Meeting is set as November 30, 2022. The notice, agenda and associated material have been despatched to shareholders via mail and the notice, agenda and related financial statements in the form of the relevant Form 20-F filing are available on the Company's website at https://ir.tizianalifesciences.com/shareholder-services/annual-ge

      12/6/22 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

      NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a corporate update, including its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS) such as non-active secondary-progressive Multiple Sclerosis (SPMS), Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, "We look forward to leveraging the exciting clinical and preclinical results from our

      11/10/22 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

      NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company's novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment. Date:Wednesday, September 8, 2021  Time:4:15 p.m. Eastern Time  Live Call:+1-877-407-9716 (U.S. Toll-Free) or +1-201-493-6779 (International)

      9/7/21 2:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Leadership Updates

    Live Leadership Updates

    See more
    • Tiziana Life Sciences Appoints New Chief Executive Officer

      NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. "We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Founder and Executive Chairman of the Board. " Ivor has an invaluable track record in creating substantial value for biotech and pharma companies with his strategic vision in building in

      8/19/24 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

      NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious "Giants of MS" award for his outstanding contributions in the area of multiple sclerosis (MS) research. The award ceremony will take place on May 30, 2024 at the Consortium of Multipl

      5/30/24 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

      Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023. In this role, Dr. Clementi will be responsible for overseeing the company's development strategies and advancing its portfolio of groundbreaking therapeutic candidates. Dr. Clementi brings with

      8/23/23 10:30:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care